Selecta 1064: photodisruption of ocular tissue using light energy emitted by a Nd:YAG laser, including discission of the posterior capsule of the eye (posterior capsulotomy), and discission of pupillary membranes (pupillary membranectomy) in aphakic and pseudophakic patients, and iridotomy/iridectomy
Selecta SLT: selective laser trabeculoplasty
Selecta Duo: photodisruption of ocular tissue using light energy emitted by a Nd: Y AG laser, including discission of the posterior capsule of the eye (posterior capsulotomy), and discission of pupillary membranes (pupillary membranectomy) in aphakic and pseudophakic patients, and iridotomy/iridectomy; and selective laser trabeculoplasty
The Selecta 1064, Selecta SLT and Selecta Duo Ophthalmic Lasers are also intended for use as a diagnostic slit lamp, specifically, An AC-powered slit lamp biomicroscope intended for use in eye examination of the anterior segment, from the cornea epithelium to the posterior capsule. It is used to aid in the diagnosis of diseases or trauma which affects the structural properties of the anterior segment.
LaserLink S: laser delivery system for use by an ophthalmologist in the treatment of ocular tissue; laser delivery system indicated for use for a variety of ophthalmic uses, including the indications specified in the laser operator manual. Refer to the laser operator manual, Indications for Use section.

Device Description

The Lumenis Selecta is a fully integrated flash lamp pumped, solid state, Nd: YAG ophthalmic surgical laser system intended for use in the treatment of ocular pathology and for use as a diagnostic slit lamp.
The Family of Selecta Ophthalmic Lasers, Delivery Device and Accessories consists of the following models:

Selecta 1064° a Nd: YAG laser providing Q-switched laser pulses at a wavelength of 1064nm for use in photodisruption of ocular tissue (posterior capsulotomy, pupillary membranectomy, iridotomy). The 1064nm treatment beam delivers a 4 nsec, 0.3-10mJ adjustable and selectable single, double or triple pulse of energy. It is conditioned through beam shaping optics to generate a photodisruption micro pulse of plasma at a precision adjustable location relative to the visual focal plane (located at slit lamp center of rotation) and along the slit lamp objective lens axis. A twin aiming beam is also focused by the slit lamp objective to a converging 20um spot located at the focal point of the lens. The focal point of photodisruption is adjustable 0-350um in the posterior direction by the physician relative to this convergence of the twin aiming beams.
Selecta SLT® -- a Nd: YAG laser providing Q-switched frequency doubled pulses at a wavelength of 532nm for use in selective laser trabeculoplasty. The treatment beam delivers a 4nsec, 0.1-2mJ adjustable single pulse of energy. The aiming and treatment beams are coaxial with each other and focused by the slit lamp objective to a 400um spot at the focal point of the lens.
Selecta Duo a Nd:YAG laser providing Q-switched laser pulses at a wavelength of 1064 nanometers for use in photodisruption or Q-switched frequency doubled pulses at a wavelength of 532nm for use in selective laser trabeculoplasty, depending upon the mode selected. The Selecta Duo contains two aiming beam modules that produce a single beam for the 532nm mode and a dual beam for the 1064nm mode, respectively.
For each Selecta model, the physician controls delivery of laser energy from the Selecta remote control display unit and activates the treatment laser beam with a footswitch or joystick pushbutton. In addition, a laser slit lamp delivery adaptor, the LaserLink S, may be coupled to each of the above Selecta models and connected to a currently cleared Lumenis 532nm photocoagulator to allow the physician to use the Selecta slit lamp to deliver 532nm continuous wave laser energy for photocoagulation.

AI/ML Overview

The provided text is a 510(k) summary for the Lumenis Family of Selecta Ophthalmic Laser Systems, Delivery Device and Accessories. It focuses on demonstrating substantial equivalence to predicate devices rather than proving performance against specific acceptance criteria through a dedicated study.

Therefore, the document does not contain the information requested regarding acceptance criteria and a study that demonstrates the device meets these criteria in the format specified.

Specifically, the document does not provide:

A table of acceptance criteria and reported device performance.
Sample sizes used for a test set, data provenance, or details about training sets.
Information on the number or qualifications of experts used to establish ground truth, adjudication methods, MRMC studies, or standalone algorithm performance.
The type of ground truth used (e.g., pathology, outcomes data).

Instead, the submission states:

Rationale for Substantial Equivalence: The primary argument is that the device has "the same intended uses and indications for use as the predicate devices, and have similar technological characteristics as the predicate devices - treatment wavelength, laser media, mode of operation, energy output, pulse duration, pulse settings, spot sizes, aiming beam, cooling system, laser energy delivery control (footswitch/ handswitch), and delivery system." (Section VI)
Performance Data: "System and software hazard analysis information, software verification and validation information, and clinical literature were submitted in conjunction with this Premarket Notification submission. The determination of substantial equivalence was based upon the comparison of the technical characteristics between the Family of Selecta Ophthalmic Laser Systems, Delivery Device and Accessories and the predicate laser systems and the evaluation of the performance data." (Section VII)

This indicates that the performance data submitted was likely focused on technical specifications and safety analyses to demonstrate equivalence, rather than a clinical study with detailed performance metrics against pre-defined acceptance criteria for diagnostic or treatment accuracy.

Summary

{0}------------------------------------------------

K 051944

SEP 3 0 2005 Attachment 10 510(k) Summary Statement

I. General Information

Submitter:

Lumenis, Inc. 2400 Condensa Street Santa Clara, California, U. S. A. 95051-0901

Contact Persons:

Karen L. Baker

Summary Preparation Date: July 15, 2005

II. Names

Device Names:

Family of Selecta Ophthalmic Laser Systems, Delivery Device and Accessories Selecta 1064 Ophthalmic Laser System Selecta SLT Ophthalmic Laser System Selecta Duo Ophthalmic Laser System LaserLink S

Primary Classification Name: 79, General and Plastic Surgery Panel

GEX, Laser powered surgical instrument

III. Predicate Devices

Lumenis Selecta Duet (K021550) ●
Coherent Popeye Ophthalmic Laser and Coherent Popeye Ophthalmic Laser in . Combination with the Coherent Ultima 2000 Laser Photocoagulator Coherent Popeye Nd: YAG Ophthalmic Laser Systems (K973470)
t Selecta 7000 Frequency Doubled Q-Switched Nd: Y AG Ophthalmic Laser (K004006)
LaserLink Z-1000 (K022181) .

IV. Product Description

The Family of Selecta Ophthalmic Lasers, Delivery Device and Accessories consists of the following models:

I) Selecta 1064° a Nd: YAG laser providing Q-switched laser pulses at a wavelength of 1064nm for use in photodisruption of ocular tissue (posterior capsulotomy, pupillary membranectomy, iridotomy). The 1064nm treatment beam delivers a 4 nsec, 0.3-10mJ adjustable and selectable single, double or triple pulse of energy. It is

{1}------------------------------------------------

conditioned through beam shaping optics to generate a photodisruption micro pulse of plasma at a precision adjustable location relative to the visual focal plane (located at slit lamp center of rotation) and along the slit lamp objective lens axis. A twin aiming beam is also focused by the slit lamp objective to a converging 20um spot located at the focal point of the lens. The focal point of photodisruption is adjustable 0-350um in the posterior direction by the physician relative to this convergence of the twin aiming beams.

1. Selecta SLT® -- a Nd: YAG laser providing Q-switched frequency doubled pulses at a wavelength of 532nm for use in selective laser trabeculoplasty. The treatment beam delivers a 4nsec, 0.1-2mJ adjustable single pulse of energy. The aiming and treatment beams are coaxial with each other and focused by the slit lamp objective to a 400um spot at the focal point of the lens.
1. Selecta Duo a Nd:YAG laser providing Q-switched laser pulses at a wavelength of 1064 nanometers for use in photodisruption or Q-switched frequency doubled pulses at a wavelength of 532nm for use in selective laser trabeculoplasty, depending upon the mode selected. The Selecta Duo contains two aiming beam modules that produce a single beam for the 532nm mode and a dual beam for the 1064nm mode, respectively.

For each Selecta model, the physician controls delivery of laser energy from the Selecta remote control display unit and activates the treatment laser beam with a footswitch or joystick pushbutton. In addition, a laser slit lamp delivery adaptor, the LaserLink S, may be coupled to each of the above Selecta models and connected to a currently cleared Lumenis 532nm photocoagulator to allow the physician to use the Selecta slit lamp to deliver 532nm continuous wave laser energy for photocoagulation.

V. Indications for Use

photodisruption of ocular tissue using light energy emitted by a Nd: Y AG Selecta 1064: laser, including discission of the posterior capsule of the eye (posterior capsulotomy), and discission of pupillary membranes (pupillary membranectomy) in aphakic and pseudophakic patients, and iridotomy

selective laser trabeculoplasty Selecta SLT:

photodisruption of ocular tissue using light energy emitted by a Nd: YAG Selecta Duo: laser, including discission of the posterior capsule of the eye (posterior capsulotomy), and discission of pupillary membranes (pupillary membranectomy) in aphakic and pseudophakic patients, and iridotomy; and
selective laser trabeculoplasty

The Selecta 1064, Selecta SLT and Selecta Duo Ophthalmic Lasers are also intended for use as a diagnostic slit lamp, specifically,

An AC-powered slit lamp biomicroscope intended for use in eye examination of the anterior segment, from the cornea epithelium to the posterior capsule. It is used to aid in

{2}------------------------------------------------

the diagnosis of diseases or trauma which affects the structural properties of the anterior segment

LaserLink S: laser delivery system for use by an ophthalmologist in the treatment of ocular tissue;
laser delivery system indicated for use for a variety of ophthalmic uses, including the indications specified in the laser operator manual. Refer to the laser operator manual, Indications for Use section.

VI. Rationale for Substantial Equivalence

The Family of Selecta Ophthalmic Laser Systems, Delivery Device and Accessories have the same intended uses and indications for use as the predicate devices, and havens imilar technological characteristics as the predicate devices - treatment wavelength, laser media, mode of operation, energy output, pulse duration, pulse settings, spot sizes, aiming beam, cooling system, laser energy delivery control (footswitch/ handswitch), and delivery system - as the predicate devices, and therefore are substantially equivalent to the predicate devices referenced in Section III.

Performance Data VII.

System and software hazard analysis information, software verification and validation information, and clinical literature were submitted in conjunction with this Premarket Notification submission. The determination of substantial equivalence was based uppor the comparison of the technical characteristics between the Family of Selecta Ophthalmic Laser Systems, Delivery Device and Accessories and the predicate laser systems and the evaluation of the performance data.

VIII. Conclusion

The Family of Selecta Ophthalmic Laser Systems, Delivery Device and Accessories are substantially equivalent to similar predicate laser devices, delivery systems and accessories. The Family of Selecta Ophthalmic Laser Systems, Delivery Device and Accessories share the same intended use, indications for use, and technological characteristics as the predicate laser systems.

{3}------------------------------------------------

Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH AND HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized symbol that resembles a human figure with three arms or lines extending upwards, representing health, services, and the human aspect of the department's mission.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

SEP 3 0 2005

Ms. Karen L. Baker Manager, Regulatory Affairs Lumenis. Inc. 2400 Condensa Street Santa Clara, California 95051

Re: K051944

Trade/Device Name: Family of Selecta Ophthalmic Laser Systems (Selecta SLT, Selecta 1064, and Selecta Duo) and Delivery Device (LaserLink S) and Accessories Regulation Number: 21 CFR 886.4390 Regulation Name: Ophthalmic laser Regulatory Class: II Product Code: HQF, GEX Dated: July 15, 2005 Received: July 18, 2005

Dear Ms. Baker:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{4}------------------------------------------------

Page 2- Ms. Karen L. Baker

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,
Mark A. Millman

Mark N. Melkerson Acting Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{5}------------------------------------------------

Attachment 2 Indications for Use Statement as Requested by FDA

510(K) Number (if Known):

K 051944

Device Name: Family of Selecta Ophthalmic Laser Systems (Selecta SLT, Selecta 1064, and Selecta Duo) and Delivery Device (LaserLink S) and Accessories

Indications for Use:

photodisruption of ocular tissue using light energy emitted by a Nd:YAG Selecta 1064: laser, including discission of the posterior capsule of the eye (posterior capsulotomy), and discission of pupillary membranes (pupillary membranectomy) in aphakic and pseudophakic patients, and iridotomy/iridectomy

selective laser trabeculoplasty Selecta SLT:

photodisruption of ocular tissue using light energy emitted by a Nd: Y AG Selecta Duo: laser, including discission of the posterior capsule of the eye (posterior capsulotomy), and discission of pupillary membranes (pupillary membranectomy) in aphakic and pseudophakic patients, and iridotomy/iridectomy; and
selective laser trabeculoplasty

The Selecta 1064, Selecta SLT and Selecta Duo Ophthalmic Lasers are also intended for use as a diagnostic slit lamp, specifically,

An AC-powered slit lamp biomicroscope intended for use in eye examination of the anterior segment, from the cornea epithelium to the posterior capsule. It is used to aid in the diagnosis of diseases or trauma which affects the structural properties of the anterior segment.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON AND THER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)
Division of General, Restorative, and Neurological Devices

510(k) Number	K051944
---------------	---------

Prescription Use:	✓ (Per 21 CFR 801.109)Optional Format 1-2-96	OR	Over-The-Counter Use: ________
-------------------	----------------------------------------------------------------------------------------------------------------	----	--------------------------------

{6}------------------------------------------------

Attachment 2, Continued Indications for Use Statement as Requested by FDA

510(K) Number (if Known):

K051944